Humanigen

Humanigen Market capitalization

Delisted

The The market capitalization of Humanigen (HGENQ) as of Nov 20, 2026 is 119.00 USD. In the previous year, The market capitalization was 119.00 USD — a change of 0.00% (lower).

Market capitalization

119.00USD

YoY

0.00%

Last updated:

In 2022, Humanigen's market cap stood at 119.00 USD, a 0.00% increase from the 119.00 USD market cap in the previous year.

The Humanigen Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2015
119.00 USD
Jan 1, 2016
119.00 USD
Jan 1, 2017
119.00 USD
Jan 1, 2018
119.00 USD
Jan 1, 2019
119.00 USD
Jan 1, 2020
119.00 USD
Jan 1, 2021
119.00 USD
Jan 1, 2022
119.00 USD
The Humanigen Market capitalization history
YEARMarket capitalizationYoY
119.00USD0.00%
119.00USD0.00%
119.00USD0.00%
119.00USD0.00%
119.00USD0.00%
119.00USD0.00%
119.00USD0.00%
119.00USD0.00%
119.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humanigen Stock analysis

What does Humanigen do? Humanigen Inc is a pharmaceutical company specializing in the discovery, development, and marketing of drugs, therapies, and solutions in the field of medical research. The company was originally founded in 2000 and is headquartered in Burlingame, California. One major focus of Humanigen Inc is the treatment of severe and life-threatening diseases such as cancer or HIV/AIDS that have not been sufficiently addressed by other medications. The company has developed a range of special technologies that enable it to develop innovative and effective therapies and drugs. An important aspect of Humanigen Inc's business model is collaboration with other companies, institutions, and research facilities worldwide. Through partnerships and cooperation, the company is able to cover the entire spectrum of research and development, allowing it to develop treatment options even faster and more effectively. Humanigen Inc has several different divisions and products designed for various applications. An important subsidiary of the company is the Humanigen Center for HIV Cure Research, which specifically focuses on combating HIV. There, the company works closely with scientists, researchers, and partners to develop new and innovative treatment options. Another important product of Humanigen Inc is the drug Lenzilumab. Lenzilumab is an antibody used to treat severe and life-threatening diseases such as cancer and COVID-19. Lenzilumab has shown great promise in clinical trials and could be the key to developing new and effective treatment options. In addition, Humanigen Inc has filed a variety of patents that enable it to develop new and innovative technologies in medical research. Many of these technologies are also licensed by other companies and research institutions, promoting the growth and expansion of Humanigen Inc. In recent years, the company has also placed a major focus on the field of digital technology. By utilizing big data, artificial intelligence, and other digital technologies, Humanigen Inc is able to develop new therapy options even faster and more effectively, catering specifically to the needs of patients and doctors. Overall, Humanigen Inc is an innovative and rapidly growing company focused on the development of new and effective treatment options for serious diseases. Through collaboration with other companies and institutions, the development of new technologies, and a targeted focus on the needs of patients and doctors, the company is able to respond even faster and more effectively to challenges in the field of medical research. Humanigen is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Humanigen's Market Capitalization

Humanigen's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Humanigen's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Humanigen's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Humanigen’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Humanigen stock

The market capitalization of Humanigen is 119.00 USD in 2022.

The market capitalization of Humanigen changed from 119.00 USD to 119.00 USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Humanigen since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Humanigen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Humanigen

All Key Metrics — Humanigen